retatrutide clinical trial phase retatrutide Eli Lilly infiltrates anti-obesity market as III for begins Triple hormone receptor agonist retatrutide

Without a documented comorbidity, a BMI of 28 alone does not meet the FDA threshold for weight management indications

37 GLP-1 RA-MWL has a direct lipolytic effect in addition to inhibiting lipid storage, reducing adipose-derived stem cell (ADSC) populations and attenuating adipocyte proliferation and differentiation

For women experiencing menopausal weight gain, GLP-1 therapy combined with perimenopause management can be particularly effective

Retatrutide Status Retatrutide remains in Phase 3 clinical trials with FDA approval projected for late 2026 to early 2027

Xin Lu, orcid.org/0000-0003-1036-3369 Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

Understanding the pharmacokinetics of each compound you use, whether GLP-1 or otherwise, is the foundation of effective and safe protocol management